Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sirolimus for relapsed or refractory acquired chronic pure red cell aplasia
jRCTs031230310Completed
- Sponsor
- Japanese Society of Hematology
- Start
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of sirolimus in pure red cell aplasia (PRCA) and acquired pure red cell aplasia (PRCA), sponsored by Japanese Society of Hematology. Primary endpoint: Change in hemoglobin at week 24 or discontinuation. Started Aug 2023; status: completed.
02
Drugs
sirolimus
03
Conditions
pure red cell aplasia (PRCA)acquired pure red cell aplasia (PRCA)
Beyond the preview
Go deeper on jRCTs031230310.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031230310.